VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

MDS 2020 | Opicapone shows better motor performance in Parkinson’s disease compared to entacapone

Joaquim Ferreira, MD, PhD, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, discusses how the newly licensed COMT inhibitor opicapone has shown to have more benefits over the older treatment entacapone. Opicapone displays better motor performance by prolonging the ‘on-time’ in Parkinson’s disease patients. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).